Elsevier

Clinical Therapeutics

Volume 25, Issue 6, June 2003, Pages 1654-1669
Clinical Therapeutics

Consensus statement
A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A

https://doi.org/10.1016/S0149-2918(03)80161-3Get rights and content

Abstract

A meeting of 14 transplant and pharmacokinetic specialists from Europe and North America was convened in November 2001 to evaluate scientific and clinical data regarding the use of different formulations of cyclosporin A (CsA). The following consensus was achieved. (1) CsA is a critical-dose drug with a narrow therapeutic window. Clinical outcomes after transplantation are affected by the pharmacokinetic properties of CsA, particularly by its bioavailability, and by intrapatient variability in CsA exposure. (2) Standard bioequivalence criteria do not address differences in CsA pharmacokinetics between transplant recipients and healthy volunteers, or between subpopulations of transplant recipients. (3) In some circumstances, currently available formulations of CsA that meet standard bioequivalence criteria are likely to be nonequivalent with respect to pharmacokinetic characteristics. (4) The choice of CsA formulation can affect the short- and long-term clinical outcome. Currently, there is a lack of clinical comparisons between generic CsA formulations and the Neoral® formulation (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey). Initial retrospective data from the Collaborative Transplant Study suggest that use of generic CsA formulations may result in reduced graft survival at 1 year. (5) Management of transplant recipients by monitoring Neoral concentrations 2 hours after dosing (C2) reduces the incidence and severity of acute rejection compared with monitoring of trough concentrations with no increase in toxicity. C2 monitoring has been developed based on the pharmacokinetics of Neoral only and has not been evaluated or validated for generic formulations of CsA. (6) The major costs of care after transplantation relate to the management of poor clinical outcomes and toxicity. CsA formulations with different pharmacokinetic properties may be associated with varying clinical outcomes, which would be expected to affect total health care costs. (7) The transplant physician is responsible for selecting immunosuppressive agents and formulations for his or her patients. Any switch between CsA formulations in a particular patient should take place only in a controlled setting with adequate pharmacokinetic monitoring.

References (51)

  • B.D. Kahan et al.

    Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

    Transplantation

    (1996)
  • B.D. Kahan et al.

    Challenges in cyclosporine therapy: The role of therapeutic monitoring by area under the curve monitoring

    Ther Drug Monit

    (1995)
  • J.L. Colaizzi et al.

    Critical therapeutic categories: A contraindication to generic substitution?

    Clin Ther

    (1986)
  • Committee for Proprietary Medicinal Products
  • Food and Drug Administration Center for Drug Evaluation and Research

    Approved Drug Products with Therapeutic Equivalence Evaluations

  • A. Johnston et al.

    Simple bioequivalence criteria: Are they relevant to critical dose drugs? Experience gained from cyclosporine

    Ther Drug Monit

    (1997)
  • R.J. Ptachcinski et al.

    Cyclosporine kinetics in healthy volunteers

    J Clin Pharmacol

    (1987)
  • G.F. Cooney et al.

    Cyclosporin pharmacokinetics in paediatric transplant recipients

    Clin Pharmacokinet

    (1997)
  • S. Dunn et al.

    Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients

    Transplantation

    (1997)
  • T.J. Schroeder et al.

    Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations

  • A. Lindholm et al.

    The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss

    Transplantation

    (1993)
  • G.F. Cooney et al.

    Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis

    Transplantation

    (1990)
  • K.K. Tan et al.

    Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis

    Ther Drug Monit

    (1990)
  • B.D. Kahan et al.

    Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals

    Transplantation

    (1995)
  • S.G. Pollard et al.

    Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients

    Transplantation

    (1999)
  • Cited by (69)

    • Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population

      2022, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Neoral® was shown to outperform the marketed SEDDS formulation (Sandimmune®). Several studies have compared safety and efficacy between conventional cyclosporine and microemulsified cyclosporine in children with nephrotic syndrome [127–129] and recipients of renal transplants [130,131]. These studies indicate that there may be considerable differences in CsA exposure when different formulations are administered.

    • Cardiovascular events in patients with systemic lupus erythematosus

      2014, Cor et Vasa
      Citation Excerpt :

      Metabolic effects comprising glucose tolerance impairment are described in about 5% of patients treated with cyclosporine A, this drug also being responsible for arterial hypertension or its acceleration. Some 1–10% of patients using cyclosporine A will suffer a myocardial infarction [22]. Cyclophosphamide and methotrexate are – in about 1% of cases – associated with veno-occlusive thromboembolic events concerning mostly peripheral vessels and with myocardial infarctions.

    • Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs

      2011, Journal of Controlled Release
      Citation Excerpt :

      Since it was introduced in the first 1980s, cyclosporine A has improved the outcome of solid organ transplantation. Unfortunately, CsA is characterised by high intra- and inter-patient pharmacokinetic variability and poor bioavailability [3–5]. Furthermore, the tolerability profile of cyclosporine is characterised by a number of potentially serious adverse effects that are related to exposure, including acute or chronic nephrotoxicity, hypertension and neurotoxicity [6].

    View all citing articles on Scopus
    View full text